Healthcare Industry News: oral cancer
News Release - May 30, 2007
Zila Appoints Dr. George J. Vuturo to Its Board of Directors and Audit CommitteePHOENIX--(HSMN NewsFeed)--Zila, Inc. (NASDAQ GM: ZILA), has appointed George J. Vuturo to its Board of Directors. Dr. Vuturo will also join the Audit Committee and will bring the number of Board Members to six.
Dr. Vuturo, 57, has over 28 years of experience in the pharmaceuticals industry and is recognized as a leader in the field of medical education technology. In 1995, Dr. Vuturo founded Designing Solutions, L.L.C. and Professional Education Services Group, L.L.C., both are healthcare services companies that specialize in providing professional medical education programs to physicians, pharmacists, dentists, nurses, and other healthcare providers. Dr. Vuturo has served as managing partner of both companies since their inception. From 2004 to 2005, Dr. Vuturo was a member of the Board of Directors of QLT, Inc., a publicly-traded biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative therapies. From 2001 to 2004, Dr. Vuturo was a member of the Board of Directors and, at various times, served on the Executive, Compensation, Audit and Nominations Committees of Atrix Laboratories, Inc. Atrix Laboratories, a former publicly-traded specialty pharmaceutical company, is focused on advanced drug delivery. In 2005, Atrix Laboratories merged with QLT, Inc. Dr. Vuturo received his Ph.D. in Health Care Administration from the University of Florida, where he also received his Bachelor of Science in Pharmacy. Additionally, Dr. Vuturo holds a B.S. in Biology from Fairfield University.
David R. Bethune, Chairman of the Board of Zila, commented "Dr. Vuturo has extensive experience in the healthcare and pharmaceutical industries and serves on a number of pharmacy and medical boards, including the Board of Directors of the American Foundation for Pharmacy Education (AFPE), and the National Board for the Center of Health Sciences at the University of Florida Medical Center. He will be a valuable addition to the Board and will contribute significantly to the continued growth of Zila's oral cancer detection business."
About Zila, Inc.
Zila, Inc., headquartered in Phoenix, is a leading oral cancer diagnostic company focused on the prevention and treatment of oral disease:
Zila is dedicated to establishing ViziLite® Plus as the new standard of care within the medical community for the early detection of oral abnormalities that could lead to cancer, with an initial focus on the dental market through Pro-Dentec®, a leading designer, manufacturer and marketer of Soft Tissue Management (STM®) products. Sold exclusively and directly to dental professionals, Pro-Dentec's core products include the Rota-dent® Professional Powered Brush, the Pro-Select3® Piezo-Ultrasonic Scaler System and a suite of pharmaceutical STM® products for both in-office and home-care use.
Zila is also focused on achieving regulatory approval for the next generation oral cancer diagnostic, OraTest®, followed by the development of additional applications of its cancer detection technologies.
For more information about Zila, visit www.zila.com.
Safe Harbor Statement
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements are based largely on Zila's expectations or forecasts of future events, can be affected by inaccurate assumptions and are subject to various business risks and known and unknown uncertainties, a number of which are beyond the Company's control. Therefore, actual results could differ materially from the forward-looking statements contained herein. A wide variety of factors could cause or contribute to such differences and could adversely impact revenues, profitability, cash flows and capital needs. There can be no assurance that the forward-looking statements contained in this press release will, in fact, transpire or prove to be accurate, and we disclaim any obligation to update or revise any such forward-looking statements. For a more detailed description of these and other cautionary factors that may affect Zila's future results, please refer to the documents we file with the Securities and Exchange Commission, including our Form 10-K for the fiscal year ended July 31, 2006, our Current Report on Form 8-K filed on December 28, 2006, and our Form 10-Q for the quarter ended January 31, 2007.
Source: Zila, Inc
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.